Key Points
Teladoc Health (NYSE: TDOC) was a rock star during the early days of the pandemic. It quickly became a stock market darling as its revenue soared due to the telemedicine services it provided. However, Teladoc was unable to maintain that pace, and the past few years have been horrendous for the stock. The stock is down nearly 92% over the past six years.
Here’s the even worse news: Teladoc Health is unlikely to bounce back anytime soon, so investors should stay away from the stock. Here are three reasons why.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Image source: Getty Images.
1. Stiff competition
The success Teladoc saw during the early days of the pandemic attracted significant competition. There are now many alternative platforms, including some created by well-established, highly successful corporations like Amazon. The tech giant’s strong brand name and its ecosystem of more than 180 million Prime members in the U.S. is helping power its ambitions in the healthcare industry.
Further, Amazon isn’t the only company leveraging these advantages in the battle for telemedicine services. Some insurance companies with large existing client bases can bypass third-party virtual care platforms and create their own similar ones. All of these dynamics pose a significant threat to Teladoc’s prospects. True, a company can be successful despite significant competition, but that’s only one of Teladoc’s many problems.
2. A growth driver no longer
One of Teladoc’s most important growth drivers was its virtual mental health therapy service, BetterHelp. However, this segment has been struggling in recent years, largely due to competition. BetterHelp is now a deadweight on Teladoc’s top-line growth while it continues to lose paying members. This suggests that, although it’s possible to succeed in a sea of competitors, Teladoc has yet to fully grasp how to achieve this.
3. Consistent net losses
Teladoc is not yet a profitable company. That alone wouldn’t necessarily be a good reason to avoid the stock. Many corporations are attractive despite showing a loss on the bottom line. However, these tend to be businesses that record strong revenue growth and are establishing themselves as leaders in industries with massive room to grow. That description does not fit Teladoc.
Sales growth has been slow — at best — and at times nonexistent, for a few years now, and the company has been losing market share. Now, the company has tried to turn things around and it hopes that its international expansion efforts will help it bounce back. And in fairness, international revenue has been growing faster for Teladoc.
But can it maintain that momentum? My view is that Teladoc is likely to encounter the same problems abroad as it did in the U.S, eventually. That’s why it’s not worth investing in the stock today.
Should you buy stock in Teladoc Health right now?
Before you buy stock in Teladoc Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Teladoc Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $490,703!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,157,689!*
Now, it’s worth noting Stock Advisor’s total average return is 966% — a market-crushing outperformance compared to 194% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of January 4, 2026.
Prosper Junior Bakiny has positions in Amazon. The Motley Fool has positions in and recommends Amazon and Teladoc Health. The Motley Fool has a disclosure policy.